Sanofi (NASDAQ:SNY) Short Interest Update

Sanofi (NASDAQ:SNY - Get Free Report) was the target of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 4,530,000 shares, a drop of 48.7% from the November 15th total of 8,830,000 shares. Approximately 0.2% of the company's shares are sold short. Based on an average trading volume of 2,020,000 shares, the days-to-cover ratio is presently 2.2 days.

Wall Street Analysts Forecast Growth

SNY has been the subject of a number of recent analyst reports. Citigroup upgraded shares of Sanofi to a "strong-buy" rating in a research report on Tuesday, September 17th. StockNews.com cut Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday. Two analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $57.50.

Sanofi Stock Down 2.1 %

Shares of SNY stock traded down $1.00 during trading hours on Thursday, hitting $46.99. 2,601,752 shares of the company were exchanged, compared to its average volume of 2,060,430. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The business has a 50 day moving average of $51.36 and a two-hundred day moving average of $52.09. The company has a market capitalization of $119.25 billion, a PE ratio of 24.48, a PEG ratio of 1.23 and a beta of 0.58.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.22 by $1.35. The firm had revenue of $13.44 billion during the quarter, compared to analysts' expectations of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company's revenue was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.55 EPS. Analysts anticipate that Sanofi will post 4.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sanofi

Several institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp grew its holdings in shares of Sanofi by 19.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company's stock valued at $417,017,000 after acquiring an additional 1,370,232 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC grew its stake in Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company's stock valued at $288,381,000 after purchasing an additional 3,164,092 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company's stock worth $208,106,000 after purchasing an additional 395,744 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in shares of Sanofi by 8.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company's stock worth $157,803,000 after purchasing an additional 246,224 shares in the last quarter. Finally, Federated Hermes Inc. boosted its holdings in shares of Sanofi by 26.5% in the 2nd quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company's stock valued at $155,950,000 after buying an additional 673,172 shares during the last quarter. Institutional investors own 10.04% of the company's stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.